Journal of Internal Medicine Concepts & Practice ›› 2024, Vol. 19 ›› Issue (05): 333-336.doi: 10.16138/j.1673-6087.2024.05.09

• Review • Previous Articles     Next Articles

Research progress of coagulation factor XIII and venous thromboembolism

XIE Xuemeng1, HU Ling2()   

  1. 1. Department of Critical Care Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China
    2. Clinical Medicine College, Jining Medical University, Jining 272067, China
  • Received:2024-02-05 Online:2024-10-28 Published:2025-01-16

Abstract:

Venous thromboembolism (VTE) is the third most common cardiovascular disease worldwide, and its incidence continues to rise. Coagulation factor XIII (FXIII, factor XIII), also known as fibrin stabilization factor, is involved in multiple stages of the clotting cascade. Recent studies have found that FXIII is a key factor in determining the volume, structure and stability of venous thrombosis, and may play an important role in the formation, shedding or dissolution of deep venous thrombosis. This paper reviews the research progress of FXIII and VTE, in order to provide new ideas for the prevention, diagnosis and treatment of VTE.

Key words: Venous thromboembolism, Deep vein thrombosis, Pulmonary embolism, Coagulation factor XIII

CLC Number: